retatrutide to tirzepatide vs. Tirzepatide: The Next-Gen GLP-1 Showdown Switching from tirzepatide to retatrutide:

Food & Drug Administration (FDA) for general medical use

In a crossover trial, a higher-protein meal produced significantly greater postprandial GLP-1 and PYY responses and higher satiety than higher-carbohydrate or higher-fat meals

If this technology matures, it could bridge the gap between the modest effects of current probiotics and the potent effects of pharmaceutical GLP-1 agonists

Obesity should be treated like a chronic disease, and patients must continue the medication long-term to sustain the results achieved from the medication

Chronic pain conditions, including neuropathic pain, fibromyalgia, and certain types of arthritis, have also shown promising responses to Retatrutide treatment